CAJ | 학술논문

目的分析口服不同剂量X因子抑制剂利伐沙班对急性静脉血栓栓塞症患者的疗效和安全性.方法本研究为回顾性.入选阜外心血管病医院住院的急性静脉血栓栓塞症患者33例,分为3组.组1患者(n=16)起初口服利伐沙班15 mg,每日2次,持续21 d,然后改为20 mg,每日1次.组2患者(n=9)口服利伐沙班20 mg,每日1次.组3患者(n=8)口服利伐沙班10 mg,每日1次.3组患者均连续服药3个月.分析服药3d时D-二聚体下降百分比,D-二聚体下降至正常时间,住院时间,症状缓解时间,服药3个月后影像学复查结果,血栓复发时间,出血事件,肝肾功能指标.结果组1患者服药第3天D-二聚体下降百分比明显大于组2和组3[(46.12±15.42)％比(26.59±8.11)％和(25.55±14.00)％,P值分别为0.02和0.01].组1患者D-二聚体下降至正常时间明显短于组2和组3[(17.9±7.7)d比(24.1±5.1)d和(26.3±6.2)d,P值分别为0.03和＜0.01].组3有1例患者下肢深静脉血栓复发.组1和组3各1例患者出现严重出血事件.所有患者均未出现严重出血事件和肝肾功能损害.结论口服利伐沙班15 mg,每日2次,持续21 d,然后改为20 mg,每日1次的治疗方案对急性静脉血栓栓塞症患者的疗效较好,且较为安全.
목적 분석구복불동제량X인자억제제리벌사반대급성정맥혈전전새증환자적료효화안전성.방법 본연구위회고성.입선부외심혈관병의원주원적급성정맥혈전전새증환자33례,분위3조.조1환자(n=16)기초구복리벌사반15 mg,매일2차,지속21 d,연후개위20 mg,매일1차.조2환자(n=9)구복리벌사반20 mg,매일1차.조3환자(n=8)구복리벌사반10 mg,매일1차.3조환자균련속복약3개월.분석복약3d시D-이취체하강백분비,D-이취체하강지정상시간,주원시간,증상완해시간,복약3개월후영상학복사결과,혈전복발시간,출혈사건,간신공능지표.결과 조1환자복약제3천D-이취체하강백분비명현대우조2화조3[(46.12±15.42)％비(26.59±8.11)％화(25.55±14.00)％,P치분별위0.02화0.01].조1환자D-이취체하강지정상시간명현단우조2화조3[(17.9±7.7)d비(24.1±5.1)d화(26.3±6.2)d,P치분별위0.03화＜0.01].조3유1례환자하지심정맥혈전복발.조1화조3각1례환자출현엄중출혈사건.소유환자균미출현엄중출혈사건화간신공능손해.결론 구복리벌사반15 mg,매일2차,지속21 d,연후개위20 mg,매일1차적치료방안대급성정맥혈전전새증환자적료효교호,차교위안전.
Objective To compare the efficacy and safety of 3 rivaroxaban regimen in patients with venous thromboembolism (VTE).Methods This is a retrospective study.Thirty three inpatients with VTE received rivaroxaban were divided into 3 groups,in which 16 patients were treated with 15 mg rivaroxaban twice daily for 21 days then followed by 20 mg once per day till 3 months (group 1),9 patients were treated with 20 mg rivaroxaban once daily for 3 months (group 2),8 patients were treated with 10 mg rivaroxaban once daily for 3 months.The reduction rate of D-Dimer on the third therapy day,the duration of D-Dimer normalization and hospital stay as well as symptom remission,the imaging assessment results after three months treatment,rate of recurrent VTE,bleeding,liver and kidney function were compared among the 3 groups.Results The reduction rates of D-Dimer on the third therapy day were significantly higher ((46.12±15.42)％ vs.(26.59±8.11)％ and(25.55 ± 14.00)％,P =0.02,P=0.01),and the duration of D-Dimer normalization was significantly shorter ((17.9 ±7.7) days vs.(24.1 ±5.1) days and (26.3 ± 6.2) d,P =0.03,P ＜ 0.01) in group 1 than in group 2 and 3.There was one recurrent deep-vein thrombosis in group 3,one non-major bleeding in group 1 and group 3.Major bleeding or liver and kidney dysfunction were not observed in these patients.Conclusions Venous thromboembolism can be safely and effectively treated by rivaroxaban,and does of 15 mg twice daily for 21 days followed by 20 mg once daily for 3 months are superior to the other 2 tested therapy regimen in this patient cohort.